Company Overview and News

9
QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth

2018-06-19 zacks
On Jun 18, we issued an updated research report on QIAGEN N.V. (QGEN - Free Report) . The company’s business is expected to get a boost from its flourishing molecular diagnostic market, international expansion, extended test menu and growth-driving strategic collaborations. The stock carries a Zacks Rank #3 (Hold).
AMED ISRG ILMN

8
Buy These 5 Low Leverage Stocks Amid Rising Trade Tensions

2018-06-19 zacks
U.S. stocks tumbled at the beginning of this week as the trade dispute between America and China flared up, with both nations determined to impose import tariffs. Such heightened trade tensions between the world’s two biggest economies initially spooked investors and sparked a sell-off in the share market.
OSK MGP HFC AMED KLXI

22
Here's Why You Should Add Amedisys (AMED) to Your Portfolio

2018-06-19 zacks
Amedisys, Inc. (AMED - Free Report) has been gaining investor confidence on consistent positive results. Over the past six months, the company’s share price has outperformed its industry. The stock has gained 62.9% compared with 13.5% growth recorded by the industry. Also, the company has outperformed the S&P 500’s 3.8% increase.
WBA AMED CHE ILMN

12
Hologic's New Panther Fusion System Gets Health Canada Nod

2018-06-19 zacks
Hologic, Inc. (HOLX - Free Report) recently announced the receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays for respiratory virus infections.
WBA AMED ILMN HOLX

26
Medtronic's Expanded IN.PACT Admiral FDA Nod to Aid APV Arm

2018-06-18 zacks
Medtronic plc (MDT - Free Report) has made another encouraging move with respect to its Aortic & Peripheral Vascular (APV) business. The company recently announced the receipt of FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral Drug-Coated Balloon (DCB) for treating long superficial femoral artery (SFA) lesions in patients with peripheral artery disease (PAD).
HD AMED ISRG ILMN MDT

7
AMED / Amedisys, Inc. 8-K (Current Report)

2018-06-12 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AMED

23
Envision Healthcare's (EVHC) Ratings on Review for Downgrade

2018-06-12 zacks
Credit ratings giant Moody's Investors Service has placed Envision Healthcare Corporation’s ((EVHC - Free Report) ratings on review for downgrade. This followed the announcement that KKR, a private equity firm, will acquire the company for $9.9 billion in cash. The outlook also remains under review. The acquisition is expected to be completed during the fourth quarter of 2018. The ratings put under review by Moody’s include the B1 Corporate Family Rating, B1-PD Probability of Default Rating and all debt instrument ratings.
AAC AMED CHE

24
Zacks.com highlights: G-III Apparel Group, Momo, Weight Watchers International, Amedisys and Urban Outfitters

2018-06-12 zacks
Chicago, IL – June 12, 2018 - Stocks in this week’s article include: G-III Apparel Group, Ltd. (GIII - Free Report) , Momo Inc. (MOMO - Free Report) , Weight Watchers International, Inc. (WTW - Free Report) , Amedisys, Inc. (AMED - Free Report) and Urban Outfitters, Inc. (URBN - Free Report) .
TRI MOMO WTW AMED URBN LYV GIII CVA VSTO

24
5 Stocks to Snap Up on Explosive Relative Price Strength

2018-06-11 investorplace
Investors generally gauge a stock’s potential return by examining earnings growth and valuation multiples. At the same time, it’s important to measure the performance of such a stock relative to its industry or peers, or the appropriate benchmark.
MOMO WTW AMED URBN GIII

38
CVS Health's PBM Selling Season Remains Solid, Retail Grows

2018-06-11 zacks
On Jun 8, we issued an updated research report on CVS Health (CVS - Free Report) . While increasing demand for PBM (Pharmacy Benefit Management) and specialty pharmacy was a major growth driver for the stock, its dull retail performance over the last few quarters seems to have disappointed investors. The company carries a Zacks Rank #3 (Hold).
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ AMED ISRG CVS ILMN WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

15
Top Ranked Momentum Stocks to Buy for June 11th

2018-06-11 zacks
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 11th:
AMOT AMED AMWD

24
5 Stocks to Snap Up on Explosive Relative Price Strength

2018-06-11 zacks
Investors generally gauge a stock’s potential return by examining earnings growth and valuation multiples. At the same time, it’s important to measure the performance of such a stock relative to its industry or peers, or the appropriate benchmark.
XEL HSC MOMO WTW AMED URBN GIII

13
Here's Why You Should Invest in Genomic Health (GHDX) Now

2018-06-07 zacks
Genomic Health, Inc. (GHDX - Free Report) has been gaining investor confidence on consistently positive results. Over the past year, the company’s share price has outperformed its industry. The stock has gained 52.9% against the industry’s 8% fall. Also, the company has fared better than the S&P 500’s 13% gain.
AMED ISRG ILMN GHDX

7
Why Amedisys (AMED) Stock Might be a Great Pick

2018-06-07 zacks
One stock that might be an intriguing choice for investors right now is Amedisys, Inc. (AMED - Free Report) . This is because this security in the Medical - Outpatient and Home Healthcare space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board.
AMED

10
ResMed Reports Positive Results for Bilevel PAP Device Study

2018-06-07 zacks
ResMed Inc. (RMD - Free Report) recently announced positive results from a company-sponsored research, supporting the efficiency of bilevel devices. The results were presented at SLEEP, an annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society.
RMD RSMDF AMED RMD ISRG ILMN

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to AMED / Amedisys, Inc. on message board site Silicon Investor.

GIGM - GigaMedia One Nation Under Mohamed
QMDC --- QuadraMed Inc Duramed (DRMD) Synthetic Estrogen Product
Gemini Energy GNI.V previously named Arrowhead. AOW.V SMIL - Streamedia Communications
GigaMedia - GIGM Amedisys, Inc.
NovaMed Inc. GigaMedia Limited (GIGM)
CUSIP: 023436108